Email: cspc@cspc.cn
Media
News Center
Dec. 01
2023
VOLUNTARY ANNOUNCEMENT - SYH2053 INJECTION (siRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL
Nov. 29
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE SOS1 INHIBITOR (SYH2038) OBTAINS CLINICAL TRIAL APPROVAL
Nov. 23
CSPC Signs Cooperation Agreement with AstraZeneca for Joint Confirmatory Research Targeting Lung Cancer
CSPC Receives MSCI ESG A Rating for Three Consecutive Years
VOLUNTARY ANNOUNCEMENT - ALMB-0166 FOR TREATMENT OF ACUTE ISCHEMIC STROKE OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
VOLUNTARY ANNOUNCEMENT - KN026 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
